I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

The prevalence[@ref1][@ref2] and costs[@ref2] of dementia, of which Alzheimer's dementia (AD)[@ref3] is the dominant subtype, are substantial.[@ref3] AD is characterized by deficits in memory and executive function.[@ref4] Treatments have focused on pharmacotherapy,[@ref5] but from 2002--2012 the US Food and Drug Administration has cleared only 1 of 244 drugs tested[@ref6] and no therapy halts disease progression.[@ref7]

The dual-drug hyperbaric oxygen therapy (HBOT)[@ref8][@ref9] has many neurological applications.[@ref10] The first successful HBOT-treated case of AD was published in 2001.[@ref11][@ref12] The present case report is the first patient in a series of 11 HBOT-treated AD patients whose symptomatic improvement is documented with ^18^fluorodeoxyglucose positron emission tomography (^18^FDG PET).

C[ASE]{.smallcaps} H[ISTORY]{.smallcaps} {#sec1-2}
========================================

The patient is a 58-year-old, Caucasian female with 5 years of cognitive decline that accelerated 8 months pre-HBOT. Seven months pre-HBOT extensive metabolic, vitamin deficiency, serologic, rheumatologic, imaging, cardiac, and medical evaluations, including apolipoprotein E (APOE) allele testing (homozygous e3) were negative. Electroencephalogram showed diffuse slowing; neuropsychological testing demonstrated multiple cognitive deficits. Single photon emission computed tomography (SPECT) was abnormal, suggesting AD ([**Figure 1**](#F1){ref-type="fig"}). ^18^FDG PET imaging 6 months post-SPECT and 1 month pre-HBOT confirmed AD (**[Additional video 1](#SD1){ref-type="supplementary-material"}**). Medical history: natural gas inhalation-induced syncope at 8--10 years old (subsequent referral for Special Education), decades' exposure to metallurgy factory and oil refineries, chronic hypotension, and ten-year work exposure to mold pre-diagnosis. No substance abuse or family history of AD. Brother with dementia secondary to multiple concussions, substance abuse, electroconvulsive therapy. Physical exam: confusion following commands, slight tremor, decreased pinprick diffusely, bradykinesia, hyperreflexia, dysdiadochokinesia, finger-to-nose incoordination, and instability on deep knee bend, tandem gait, and Romberg. Patient refused medications except Lexapro and vitamins.

![Single photon emission computed tomography brain blood flow imaging 7 months pre-hyperbaric oxygen therapy (selected transverse slices). Note significant regional reduction in flow to left posterior temporalparietal region (white arrows).](MGR-8-181-g001){#F1}

The patient received forty 1.15 atmosphere absolute/50 minutes total treatment time, once per day, 5 days per week, HBOTs in 66 days. After 21 HBOTs the patient reported increased energy/activity level, mood, and ability to draw a correct clock face, perform activities of daily living, and work crossword puzzles. Rivastigmine patch was started and discontinued after one week due to ineffectiveness (patient report). At completion of 40 HBOTs patient reported increased memory and concentration, sleep, conversation, appetite, ability to use the computer, more good days (5/7) than bad days, resolved anxiety, and decreased disorientation and frustration. Tremor, deep knee bend, tandem gain, and motor speed were improved. Repeat ^18^FDG PET imaging one month post HBOT showed global 6.5--38% improvement in brain metabolism (**Additional Videos [2](#SD2){ref-type="supplementary-material"}--[6](#SD6){ref-type="supplementary-material"}**; **Additional Tables [1](#T1){ref-type="table"}--[3](#T3){ref-type="table"}**).

###### 

^18^Fluorodeoxyglucose positron emission tomography transverse slice cortical ribbon and posterior temporal-parietal watershed regions of interest (caudal to cephalad) pre/post-hyperbaric oxygen therapy

            Cortical   Ribbon          Posterior   Watersh   Right   Posterior   Watersh   Left
  --------- ---------- -------- ------ ----------- --------- ------- ----------- --------- ------
  38/68     520        659      26.7   431         510       18.3    329         396       20.4
  39        515        653      26.8   391         465       18.9    352         435       23.6
  40        507        635      25.2   364         444       22.0    339         413       21.8
  41        506        629      24.3   355         447       25.9    344         409       18.9
  42        499        640      28.3   366         443       21.0    334         383       14.7
  43        512        642      25.4   383         438       14.4    317         363       14.5
  44        519        657      26.6   389         434       11.6    320         359       12.2
  45        528        642      21.6   398         446       12.1    316         338       6.96
  46        508        620      22.0   388         422       8.76    321         342       6.54
                                                                                           
  Average   513        642      25.2   385         450       17.0    330         382       15.5

Note: Pre/post: pre/post-hyperbaric oxygen therapy. % Δ: (Post - Pre)/Pre × 100%.

###### 

^18^Fluorodeoxyglucose positron emission tomography coronal slice bilateral cingulate cortices regions of interest (anterior to posterior) pre/post-hyperbaric oxygen therapy

  Slice number   Pre   Post   Change   \% Change
  -------------- ----- ------ -------- -----------
  40             475   609    134      28.2
  41             511   644    133      26.0
  42             468   624    156      33.3
  43             451   624    173      38.3
  44             478   658    180      37.7
  45             486   662    176      36.2
  46             516   659    143      27.7
  47             492   608    116      23.6
  48             517   602    85       16.4
  49             546   623    77       14.1
                                       
  Average        494   631    137      28.1

Note: Pre/post: pre/post-hyperbaric oxygen therapy. Change = Post - Pre. % Change = Change/Pre × 100%.

###### 

^18^Fluorodeoxyglucose positron emission tomography sagittal slice of bilateral cingulate cortex and ROI (right to left) pre/post hyperbaric oxygen therapy

  Slice \#   Pre   Post   Change   \% Change
  ---------- ----- ------ -------- -----------
  60/128     430   553    123      28.6
  61         454   569    115      25.3
  62         495   606    111      22.4
  63         480   554    74       15.4
  64         491   548    57       11.6
  65         476   527    51       10.7
                                   
  Average    471   559    89       19.0

Note: ROI: Regions of interest; pre/post: pre/post-hyperbaric oxygen therapy. Change = Post - Pre. %Change = Change/Pre × 100%.

Texture analysis demonstrated a global decrease in the coefficient of variation (CV) except in the Alzheimer's typical ROIs (**Additional Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}**). Two months post-HBOT the patient felt a recurrence in her symptoms. She was retreated over the next 20 months with 56 HBOTs (total 96) at the same dose, supplemental oxygen, and medications with stability of her symptoms and Folstein Mini-Mental Status exam ([**Additional Table 6**](#T6){ref-type="table"}).

###### 

Coefficient of variation in ^18^fluorodeoxyglucose positron emission tomography transverse slice of cortical ribbon and temporal-parietal watershed regions of interest (right to left) pre/post HBOT

                   Pre-HBOT   Post-HBOT                                  
  ---------------- ---------- ----------- ------ ----------- ----------- -----------
  38/68            20.1       40.4        26.7   21.4        41.9        20.3
  39               21.7       28.7        26.8   23.4        31.3        20.4
  40               23.3       32.2        27.8   26.8        32.2        22.0
  41               21.1       26.6        26.9   20.1        26.2        21.9
  42               20.5       28.1        27.7   25.5        29.8        21.7
  43               18.8       27.4        24.2   26.0        33.3        23.8
  44               22.4       25.6        22.9   27.6        33.4        22.8
  45               22.4       29.1        21.8   25.3        39.0        22.7
  46               28.1       29.9        27.4   34.4        38.6        26.5
                                                                         
  Average/change   22.0       29.8        25.8   25.6/+3.6   34.0/+4.2   22.5/-3.3

Note: HBOT: Hyperbaric oxygen therapy.

###### 

Coefficient of variation in ^18^fluorodeoxyglucose positron emission tomography coronal slice of cingulate cortices (anterior to posterior) pre/post HBOT

  Slice \#   Pre-HBOT   Post-HBOT   Change
  ---------- ---------- ----------- --------
  40/81      26.5       21.0        -5.5
  41         20.3       16.9        -3.4
  42         22.4       18.4        -4.0
  43         27.1       20.5        -6.6
  44         22.8       14.7        -8.1
  45         25.7       15.9        -9.8
  46         21.0       16.6        -4.4
  47         22.4       19.9        -2.5
  48         20.5       20.6        +0.1
  49         20.9       20.2        -0.7
                                    
  Average    23.0       18.5        -4.5

Note: HBOT: Hyperbaric oxygen therapy. Change = Post-HBOT - Pre-HBOT.

###### 

Post-40 HBOTs (after August 2016) clinic course with Folstein Mini-Mental Status Scores

  Months post 40^th^ HBOT   Number of HBOTs   Folstein Mini Mental Status   Notes
  ------------------------- ----------------- ----------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  5                         40                22                            Begins oxygen concentrator two weeks before this date at 2 L/min x 20 minutes (2-5 sessions), 3 times/week and restarts Rivastigmine patch for 4 weeks, 4 weeks post this date
  9                         70                23                            
  12                        70                23                            Restart Rivastigmine
  18                        88                19                            Discontinue Rivastigmine, start Donepezil, 5 mg/d
  22                        96                22                            

Note: HBOT: Hyperbaric oxygen therapy.

D[ISCUSSION]{.smallcaps} {#sec1-3}
========================

AD is a debilitating, costly, rapidly increasing neurological disorder for which there is no effective treatment.[@ref1][@ref2][@ref3] Etiology is multifactorial, systemic, and immune health-related from insults that occur across the spectrum of life,[@ref13] resulting in reductions of brain regional metabolism.[@ref14] Causes include infection,[@ref13] diabetes mellitus,[@ref13] metabolic disorders,[@ref7] and vascular factors.[@ref15][@ref16] Four pathological processes have been identified[@ref17]: vascular hypoperfusion of the brain (and disturbed microcirculation)[@ref18] with associated mitochondrial dysfunction,[@ref6] 2) destructive protein inclusions (intracellular neurofibrillary tangles\--phosphorylated and aggregated tau protein), and extracellular amyloid plaques,[@ref7] 3) uncontrolled oxidative stress, and 4) proinflammatory immune processes[@ref13][@ref19] secondary to microglial and astrocytic dysfunction in the brain. While the vast majority of cases are sporadic, genetic predisposition[@ref20] and epigenetic changes have been implicated.[@ref21] Diagnosis is clinical and can be confirmed with ^18^FDG PET hypometabolism in established disease,[@ref22] but is less reliable in mild cognitive impairment.[@ref22][@ref23][@ref24] Primary treatment is with acetylcholinesterase inhibitors or the N-methyl-D-aspartate receptor antagonist memantine[@ref5] which have been shown to have positive impact on AD progression[@ref25] with no significant disease-modifying effects.[@ref26]

HBOT is an epigenetic[@ref12] modulation of gene expression and suppression[@ref8][@ref9] to treat wounds[@ref9] and disease pathophysiology,[@ref27][@ref28] particularly inflammation.[@ref29] HBOT targets all four of the pathological processes of AD by: 1) affecting the microcirculation[@ref28][@ref30][@ref31][@ref32][@ref33][@ref34] mitochondrial dysfunction[@ref35][@ref36] and biogenesis,[@ref37][@ref38] 2) reducing amyloid burden and tau phosphorylation,[@ref39]3) controlling oxidative stress,[@ref40] and 4) reducing inflammation.[@ref29][@ref39][@ref41][@ref42][@ref43]

AD was suggested by SPECT and confirmed after rapid clinical decline by ^18^FDG PET hypometabolism in the typical temporal-parietal and posterior cingulate areas.[@ref14][@ref22][@ref24] Forty HBOTs improved symptoms and resting global brain metabolism (6.5--38%), including the watershed and posterior cingulate areas. The largest increases were seen in the anterior and mid-cingulate cortices and the least in the posterior cingulate and watershed areas. To our investigation these results are the largest reported global and regional improvements in resting brain metabolism in AD. Test/retest in normal has shown 0.48--9.85% increases in metabolism over 7--23 weeks,[@ref44] 25 weeks,[@ref45] and 17 days,[@ref46] while acetylcholinesterase inhibitors treatment has demonstrated regional increases,[@ref47][@ref50] no change,[@ref48] or decreases[@ref47][@ref48][@ref49] in resting metabolism. The largest increase in global metabolism (26.5%) was seen after 26 weeks of rivastigmine in responders during an activation task, but not in the temporal-parietal watershed or cingulate areas.[@ref51]

At the same time, texture results were mixed with a global decrease in CV[@ref52] except for the watershed areas which showed the opposite effect. This reduction in CV has corresponded to a visual pattern of smooth texture on SPECT seen in normal individuals and individuals with traumatic brain injury and post-traumatic stress disorder,[@ref52] carbon monoxide poisoning,[@ref53][@ref54] decompression sickness,[@ref55] near-drowning,[@ref56] and cerebral palsy[@ref56] after both a single HBOT and course of HBOT. It suggests a non-specific global effect on different brain wounding/pathologies. The differential effect on CV and less robust metabolism increases in the watershed regions implies that the patient's symptomatic improvement may be primarily due to HBOT effects on the rest of the brain. Regardless, HBOT in this patient may be the first drug to not only halt, but temporarily reverse disease progression in AD.

In conclusion, a 9-week treatment of low-pressure HBOT (40 sessions) in a patient with AD caused a significant increase in global metabolism on ^18^FDG PET imaging with concomitant symptomatic improvement. Mild symptomatic regression was treated with intermittent HBOT, normobaric oxygen, and medications to stabilize symptoms, suggesting the possibility of long-term HBOT treatment of AD with pharmacotherapy.

**Additional files**

[Additional Video 1](#SD1){ref-type="supplementary-material"}: Movie of morphed pre- to post-hyperbaric oxygen therapy ^18^fluorodeoxyglucose positron emission tomography single transverse image.

[Additional Video 2](#SD2){ref-type="supplementary-material"}: Movie of whole brain pre-(left) and post-hyperbaric oxygen therapy (right) ^18^fluorodeoxyglucose positron emission to mography transverse images (caudal to cephalad).

[Additional Video 3](#SD3){ref-type="supplementary-material"}: Movie of pre-(left) and post-hyperbaric oxygen therapy selected ^18^fluorodeoxyglucose positron emission tomography transverse images (caudal to cephalad) through temporal-parietal watershed regions of interest.

[Additional Video 4](#SD4){ref-type="supplementary-material"}: Movie of fused pre- and post-hyperbaric oxygen therapy (left) to post-hyperbaric oxygen therapy (right) ^18^fluorodeoxyglucose positron emission tomography coronal slices (anterior to posterior) through the cingulate cortices.

[Additional Video 5](#SD5){ref-type="supplementary-material"}: Movie of pre-(left) and post-hyperbaric oxygen therapy (right) ^18^fluorodeoxyglucose positron emission tomography cingulate cortices sagittal images (right to left).

[Additional Video 6](#SD6){ref-type="supplementary-material"}: Movie of three-dimensional surface ^18^fluorodeoxyglucose positron emission tomography reconstructed images pre-(left) and post-hyperbaric oxygen therapy (right).

[Additional Table 1](#T1){ref-type="table"}: ^18^Fluorodeoxyglucose positron emission tomography transverse slice cortical ribbon and posterior temporal-parietal watershed regions of interest (caudal to cephalad) pre/post hyperbaric oxygen therapy.

[Additional Table 2](#T2){ref-type="table"}: ^18^Fluorodeoxyglucose positron emission tomography coronal slice bilateral cingulate cortices regions of interest (anterior to posterior) pre/post hyperbaric oxygen therapy.

[Additional Table 3](#T3){ref-type="table"}: ^18^Fluorodeoxyglucose positron emission tomography sagittal slice bilateral cingulate cortex regions of interest (right to left) pre/post hyperbaric oxygen therapy.

[Additional Table 4](#T4){ref-type="table"}: Coefficient of variation in ^18^fluorodeoxyglucose positron emission tomography transverse slice cortical ribbon and temporal-parietal watershed regions of interest (right to left) pre/post hyperbaric oxygen therapy.

[Additional Table 5](#T5){ref-type="table"}: Coefficient of variation in ^18^fluorodeoxyglucose positron emission tomography coronal slice cingulate cortices (anterior to posterior) pre/post hyperbaric oxygen therapy.

[Additional Table 6](#T6){ref-type="table"}: Post-40 hyperbaric oxygen therapy (after August 2016) clinic course with Folstein Mini-Mental Status Scores.
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